Natera® is a global leader in cell-free DNA testing. The mission of the company is to change the management of disease worldwide with a focus on reproductive health, cancer, and organ transplantation. Signatera MRD assay is the first custom-built circulating tumor DNA (ctDNA) test for molecular residual disease detection and surveillance. This test can detect molecular recurrence prior to clinical or radiological recurrence, with clinically meaningful lead times over standard of care testing.
Natera® is a global leader in cell-free DNA testing. The mission of the company is to change the management of disease worldwide with a focus on reproductive health, cancer, and organ transplantation. Signatera MRD assay is the first custom-built circulating tumor DNA (ctDNA) test for molecular residual disease detection and surveillance. This test can detect molecular recurrence prior to clinical or radiological recurrence, with clinically meaningful lead times over standard of care testing.